Holen Sie sich die Stockscreener-App
4.08
0.73%
-0.06
Handel nachbörslich:
4.08
Schlusskurs vom Vortag:
$4.14
Offen:
$4.25
24-Stunden-Volumen:
23,603
Relative Volume:
1.25
Marktkapitalisierung:
$73.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.46M
KGV:
-7.0478
EPS:
-0.5789
Netto-Cashflow:
$-8.70M
1W Leistung:
-3.75%
1M Leistung:
-6.81%
6M Leistung:
+8.72%
1J Leistung:
-3.30%
1-Tages-Spanne:
$4.08
$4.37
1-Wochen-Bereich:
$4.08
$4.5499
52-Wochen-Spanne:
$2.66
$7.00
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
Firmenname
Alterity Therapeutics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare ATHE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.08 | 75.04M | 0 | -9.46M | -8.70M | -0.5789 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-03 | Herabstufung | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | Eingeleitet | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr Aktie (ATHE) Neueste Nachrichten
Alterity Therapeutics (NASDAQ: ATHE) sets vote on 50:1 consolidation and large option, incentive issuances - Stock Titan
[6-K] ALTERITY THERAPEUTICS LTD Current Report (Foreign Issuer) | ATHE SEC FilingForm 6-K - Stock Titan
Alterity Therapeutics appoints Ann Cunningham to board - Investing.com
Alterity Therapeutics appoints Ann Cunningham to board By Investing.com - Investing.com India
Nerves settle as oil drops - The Cairns Post
ATA Inc. (NASDAQ:AACG) Sees Large Decline in Short Interest - Defense World
Actelis Networks, Inc. (NASDAQ:ASNS) Sees Large Decline in Short Interest - Defense World
Purple Biotech Stock Scheduled to Reverse Split on Monday, March 2nd (NASDAQ:PPBT) - Defense World
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February - Defense World
Ameritas Investment Partners Inc. Raises Stock Holdings in Kratos Defense & Security Solutions, Inc. $KTOS - Defense World
Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research - Defense World
Compass Minerals International, Inc. (NYSE:CMP) Receives $22.00 Consensus Price Target from Analysts - Defense World
Benjamin Edwards Inc. Acquires 2,629 Shares of iShares Russell 1000 Value ETF $IWD - Defense World
AOT Growth & Innovation ETF (NASDAQ:AOTG) Short Interest Update - Defense World
Allspring Global Investments Holdings LLC Purchases 1,956,470 Shares of Allspring Special Large Value ETF $ASLV - Defense World
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Sees Significant Drop in Short Interest - Defense World
CaixaBank (OTCMKTS:CAIXY) Hits New 52-Week High – Still a Buy? - Defense World
ProShares Short S&P 500 (NYSEARCA:SH) Sets New 1-Year Low – Here’s Why - Defense World
Alterity Therapeutics (NASDAQ:ATHE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Insights: Alterity Therapeutics Ltd (ASX:ATH) - smallcaps.com.au
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434 - Finviz
Quantum Biopharma (QNTM) Short Interest & Short Float | Updated May 2026 - MarketBeat
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
ATHE SEC FilingsAlterity Therapeutics Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity Therapeutics announces trading halt - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
- SEC.gov
Cadrenal Therapeutics (CVKD) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Bullfrog AI (BFRG) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology By Investing.com - Investing.com India
Imunon (IMNN) Short Interest & Short Float | Updated May 2026 - MarketBeat
Quince Therapeutics (QNCX) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy - Barchart.com
What is the current Price Target and Forecast for Alterity Therapeutics LimitedSponsored ADR (ATHE) - Zacks Investment Research
Mainz Biomed (MYNZ) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
IM Cannabis (IMCC) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Portage Biotech (PRTG) Short Interest & Short Float | Updated Apr 2026 $PRTG - MarketBeat
Which stocks are gapping on Wednesday? - ChartMill
Which stocks are moving before the opening bell on Thursday? - ChartMill
Which stocks are moving before the opening bell on Tuesday? - ChartMill
Unusual volume stocks in Friday's session - ChartMill
What's going on in today's after hours session - ChartMill
Tempest Therapeutics (TPST) Short Interest & Short Float | Updated Apr 2026 $TPST - MarketBeat
Purple Biotech (PPBT) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
ATHE Financial Statements & ChartsAlterity Therapeutics LtdAdr MacroTrends - CMLviz
ATHE Pivot Points, Technical Analysis and Moving AveragesAlterity Therapeutics LtdAdr Technicals - CMLviz
Alterity Therapeutics Stock Price Forecast. Should You Buy ATHE? - StockInvest.us
Check up: A good fortnight to be a small cap health investor - Stockhead
Finanzdaten der Alterity Therapeutics Ltd Adr-Aktie (ATHE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):